Author Archives: Fredricko

Scoop: GREY’S ANATOMY on ABC – Thursday, April 27, 2017 – Broadway World

Posted on by

On the episode Dont Stop Me Now Bailey and April work to fix things between Richard and Catherine. Meanwhile, Eliza continues to pursue Arizona, and one of Alexs previous patients returns to Grey Sloan, on Greys Anatomy, THURSDAY, APRIL 27 (8:00-9:01 p.m. EDT), on The ABC Television Network.

Greys Anatomy stars Ellen Pompeo as Meredith Grey, Justin Chambers as Alex Karev, Chandra Wilson as Miranda Bailey, James Pickens Jr. as Richard Webber, Kevin McKidd as Owen Hunt, Jessica Capshaw as Arizona Robbins, Jesse Williams as Jackson Avery, Sarah Drew as April Kepner, Caterina Scorsone as Amelia Shepherd, Camilla Luddington as Jo Wilson, Jerrika Hinton as Stephanie Edwards, Kelly McCreary as Maggie Pierce, Jason George as Ben Warren, Martin Henderson as Nathan Riggs and Giacomo Gianniotti as Andrew DeLuca.

Greys Anatomy was created and is executive produced by Shonda Rhimes (Scandal, How to Get Away with Murder), Betsy Beers (Scandal, How to Get Away with Murder) and Mark Gordon (Saving Private Ryan). William Harper, Stacy McKee, Zoanne Clack and Debbie Allen are executive producers. Greys Anatomy is produced by ABC Studios.

Guest Starring is Debbie Allen as Catherine Avery.

Dont Stop Me Now was written by Andy Reaser and directed by Louis Venosta.

Greys Anatomy is broadcasted in 720 Progressive (720P), ABCs selected HTV format, with 5.1-channel surround sound.

Read the rest here:
Scoop: GREY'S ANATOMY on ABC - Thursday, April 27, 2017 - Broadway World

BYU quarterbacks, receivers need to develop chemistry, timing during offseason – Deseret News

Posted on by

PROVO BYUs Tanner Mangum and Moroni Laulu-Pututau first honed their chemistry together while serving their missions in Chile a couple of years ago.

On a couple of occasions, Mangum threw passes to Laulu-Pututau on preparation days in the city of Arica in the Chile Antofagasta Mission.

Now, Mangum is the Cougars starting quarterback and Laulu-Pututau has switched from wide receiver to tight end.

Asked to describe the rhythm they have together, Laulu-Pututau replied, fittingly, Muy bien.

As the backup last season, Mangum is focused on developing chemistry with all of his wide receivers and tight ends.

Its getting better. Every day it gets better, Mangum said. The key is just reps, especially reps going against a defense. You can throw routes on air and thats important but you have to be able to translate that into the game and into game speed, going against a live defense.

Spring practices for BYU are over, but now the real work begins heading into the 2017 season.

Receivers coach Ben Cahoon said establishing that connection between the quarterbacks and receivers requires a lot of extra time together.

That is an after-practice exercise. If theyre willing to do that, they have a chance to be decent, Cahoon said. If theyre not and if they think they can just do their work in two hours a day, then well be a mediocre passing offense, frankly. Its going to be up to them and we cant force it on them. We can encourage them. The great ones, all throughout BYU (history) have broken into churches and got the codes to the (Indoor Practice Facility) and figured out a way to spend extra time with their quarterback. That message has been sent and they know it. It remains to be seen if theyre willing to do it.

For Laulu-Pututau, that message, like hundreds of passes, has been received. Hes spending plenty of time catching balls from Mangum.

Its going well. We worked a lot (before spring ball), too, he said. We have a lot of new guys, too. Weve worked with all of the QBs. The timing is good and were a lot farther ahead than we were last year, for sure.

Having lost receivers like Nick Kurtz, Colby Pearson and Mitchell Juergens, Mangum is developing a rhythm with receivers like Jonah Trinnaman, Rickey Shumway, Talon Shumway, Akile Davis, Micah Simon and Beau Tanner.

Trinnaman didnt join the team until fall camp last season.

Its crucial for him and Tanner to get on the same page, Cahoon said. Theyve got to get their timing down. Tanners got to get used to his body language and his burst of speed. The more time they spend together, the better off well be as an offense. The chemistry is going to make a huge difference.

Simon and Davis redshirted last year and theyll be counted on to be playmakers this fall.

Their games have improved significantly. They redshirted with the idea that they needed to get bigger and faster and they werent quite ready physically to contribute, Cahoon said. That was last year. Now theyre making an impact. Ive been pleased with how hard theyre competing. That decision to redshirt them from Kalani is paying off. Theyre playing well.

Offensive coordinator Ty Detmer said his group of receivers improved during the spring.

Guys like Micah Simon stepped up and had a good spring, so did Talon Shumway. He kind of became a go-to guy for us. Jonahs making strides. Akile played a lot of DB for us on scout team and hes making strides. I feel real good with that group. They all bring a little something different to the table, kind of like the running back group. Well mix and match. You add Aleva (Hifo), who wasnt practicing (due to injury) and I have high hopes for him based off what he did his freshman year.

Continued here:
BYU quarterbacks, receivers need to develop chemistry, timing during offseason - Deseret News

Blackhawks’ third line creating chemistry and points | CSN Chicago – Comcast SportsNet Chicago

Posted on by

ANAHEIM, Calif. Ryan Hartman could see a number of reasons why he and his current linemates were finding the back of the net more lately.

"We've been with each other for a bit, that could be part of it. We're feeling comfortable with each other, finding chemistry. Sometimes it is puck luck, sometimes it may be matchups with certain teams that you pay better against," said Hartman, who will enter the final regular-season game with 19 goals. "It's been a good run. Hopefully we continue that into the playoffs and keep that four-line rotation."

Marian Hossa had the night off on Thursday when the Blackhawks lost tothe Anaheim Ducks but he, Hartman and Marcus Kruger have developed some chemistry and points in recent games. Their recent production is helping the Blackhawks keep more of that four-line rotation that worked so well for them back in February, and that they'll need in the playoffs.

"Well with that line, make sure there's contribution offensively but you know you'll get reliability defensively. Krugs has the hot stick right now and has scored some nice goals for us. But the reliability with that line is what you like about it," coach Joel Quenneville said. "Predictability is what we count on."

[VIVID SEATS:Get your Blackhawks tickets right here!]

Kruger and Hossa looked like they were onto something in the Blackhawks' first-round series against the St. Louis Blues last spring. Hossa's rebound 26-goal season, coupled with the top two lines finding success, lets the Blackhawks put Hossa elsewhere to bolster scoring depth. Add Hartman, who's been confident and unafraid to shoot no matter who he's playing with, and it's become a good combination. It just took time for them to feel each other out.

"Something like that, yeah," Hossa said. "There's lots of good potential on that line. Krugsy's steady defensively, can make some plays. Hartsy likes to go hard to the net and create space and also he has a really good shot. If he uses it more often I think it's to his advantage. It's about holding onto the puck a little more in the offensive zone and that way we can create more chances."

When the Blackhawks start the playoffs next week they should have their lineup fairly set. The fourth line is, perhaps, the only area of some question. The Blackhawks have always found success with a four-line roll that gives them the right blend of defense and production. The Hartman-Kruger-Hossa combination has provided the former consistently, the latter recently.

"We're going to need everybody," Kruger said. "We're coming close to playoffs and in the playoffs, it'll be tighter games. You need everyone bringing it because it's going to be tough to score goals."

PLYMOUTH, Mich. (AP) -- The U.S. women's hockey players threw their sticks and gloves in the air and celebrated, capping an emotionally charged two-week stretch with a 3-2 overtime win over Canada in the women's world championship final Friday night.

Hilary Knight made the postgame party possible by scoring 10:17 into the extra period to make the Americans winners on and off the ice. After threatening to sit out the tournament, they won a contentious fight with USA Hockey for better wages that will allow the country's best female hockey players to make a living playing the sport.

"I'm so proud of this team for performing the way we did after battling the way we did off the ice," said Meghan Duggan, the Americans' captain. "A lot of history was made."

The U.S. won its fourth straight world championship title and eighth in the last 10 tries against their rivals, who will get their shot at revenge as defending Olympic champions next year in South Korea.

Brianne Jenner tied it at 2 for Canada midway through the third period on a power play after Kacey Bellamy's second goal early in the period gave the Americans their first lead in the gold-medal game.

The U.S. had two power plays in the third period with 7:24 and 2:24 left along with another power play early in OT, but couldn't capitalize on the opportunities to score a go-ahead goal with an extra skater.

Canada's Meghan Agosta scored 1:01 into the game, and Bellamy tied it 3 1/2 minutes later.

Nicole Hensley stopped 28 shots for the U.S.

Canada's goaltender, Shannon Szabados, was tested much more and made 37 saves.

"She was unbelievable," Agosta said. "She kept us in the game."

The Americans boldly said they would boycott the tournament, which would've embarrassed USA Hockey at a tournament held in an arena named after the organization, if they didn't get more money and perks their male counterparts get such as flying in business class and staying at nice hotels. The landmark deal allows them to make more than $70,000 during non-Olympic years and as much as $129,000 in Olympic years, including 2018, when combined with contributions from the United States Olympic Committee.

"We knew that was going to be a bond that was unbreakable," Knight said.

USA Hockey looked like it tried to break the unified front of American women, trying to find lower-caliber players to take their spots in the world championship if Plan B became necessary.

"They didn't want to forgo this opportunity, but they were willing to do it," Dee Spagnuolo, one of the attorneys who represented the women without a fee, said during the first intermission at USA Hockey Arena. "Every time we huddled up to make tough decisions before and during negotiations, they were united and firm. This team off the ice is so united and in adverse, tense situations in games, it helps them win on the ice, too."

The U.S. carried the momentum from the win against USA Hockey into the eight-nation tournament by dominating the competition until their rivals pushed them into OT.

The Americans were the better team in the end, though, creating lots of scoring chances in the sudden-death period that could have lasted up to 20 minutes. They didn't need that much time to finish the Canadians off with a second straight OT victory in a world championship gold-medal game.

Knight, who made a no-look, between-the leg pass to set up Bellamy's second goal, was trailing on a 3-on-2 rush when Coyne dropped a pass to her and she scored from the inside of the left circle. In the 2011 world championship final, Knight also scored the gold-medal winning goal in OT.

"She's one of the best in the world and she comes up big when you need her and the moment is huge," Bellamy said. "That's what's what make her so special. When everything is on the line, she comes through clutch."

When Knight lit the goal lamp, the jubilant Americans screamed with joy and hugged in a huge huddle.

"Nothing compares to a gold-medal game against Canada," Bellamy said. "The emotions are so high. The energy in the building was incredible and it was a really fast-paced game and we had to fight to the end."

The Canadians, meanwhile, skated in the other direction. They rested their gloves on their knees and stared at the ice in silence as a sold-out crowd at USA Hockey Arena roared.

In the beginning of the tournament, Canada struggled before rallying to face off against the Americans as they've done in all 18 world championships. The Canadians opened with a 2-0 loss to the U.S. and a stunning, 4-3 setback against Finland before bouncing back with an 8-0 rout of Russia and a 4-0 win over the Finns in the semifinals.

"We were resilient the whole tournament," Agosta said.

Watchas the Blackhawks take on the Los Angeles Kingstoday on CSN and streaming live on CSNChicago.com. Coverage begins at 4:30p.m. with Blackhawks Pregame Live..Then stick around after the final buzzer to watch Blackhawks Postgame Live for highlights and analysis.

Click here to watch the game or download the NBC Sports App, your home for live streaming coverage of the Blackhawks.

Five Things to Watch:

1. Artemi Panarin bonus watch.

Well, it's Game No. 82, meaning it's the final cha
nce the Russian winger can cash in on his bonuses for the second straight year. If Panarin finishes the season among the top-10 in forwards in points, he earns a $1.725 million bonus that will carry over into next year's salary cap. He's currently ranked ninth with 73 points.

2. How many points will Patrick Kane finish with?

With Connor McDavid at 97 points and Kane at 88, it looks like there will be a new Art Ross Trophy winner. Kane's 106 points last year was a career high, and his current 88 is tied for second-best after reaching that same total during the 2009-10 season.

3. The fight for playoff roster spots.

Joel Quenneville would like to nail down his bottom-six, and doesn't prefer to rotate it often throughout the playoffs. That means a handful of players will be competing for two roster spots in the final audition of the regular season. Those players include Andrew Desjardins, John Hayden, Vinnie Hinostroza, Tomas Jurco,Dennis Rasmussen andJordin Tootoo.

4. Ryan Hartman's pursuit of 20 goals.

We mentioned this in the previous game, but it's worth paying attention to in the final contest after the Blackhawks were shut out Thursday in Anaheim. Hartman is one goal away from becoming the seventh 20-goal scorer on the team this year, and it'd be the first time the Blackhawks would accomplish that feat since 1989-90.

5. Can Blackhawks set franchise road record?

The Blackhawks have had two cracks at trying to set a new franchise record in road wins, currently sitting at 24. They reached that mark during the 2014-15 season, and will look to make it 25 today.Will third time be the charm?

- Buy tickets to tonight's game

- Check out the latest stats and standings to make sure youre ready for action

- Channel Finder: Make sure you know where to watch

- NBC Sports App FAQ: All your questions answered

- Latest on the Blackhawks: All of the most recent news and notes

- See what Blackhawks fans are talking about before, during and after the game with Blackhawks Pulse

Go here to read the rest:
Blackhawks' third line creating chemistry and points | CSN Chicago - Comcast SportsNet Chicago

Europe’s biotechnology potential hindered by investment fears – EurActiv

Posted on by

In terms of pure biotechnology, Europe has embraced innovation. However, it cannot compete with the US yet because it cannot drive private investment in the field, as well as open up the market to new products, a pharmaceutical executive told EURACTIV.com in Lyon.

Despite the EUs consistent growth in the biotech business, the EBE claims that the industry is not receiving enough support from investors, universities or research institutions, thus limiting the EUs ability to keep pace with the US in biotechnology.

The EU is lagging behind due to challenges in translating scientific innovations into successful businesses, a European Biopharmaceutical Enterprises (EBE) report claims.

Biotechnology is the use of living systems or organisms in the creation of industrial products. The growth of the biotechnology industry is important for Europe and created 10,000 new jobs and 93 medicines recommended for market authorisation by the European Medical Agency in 2015, according to the EBE.

Biotechnology could help patients across Europe gain access to innovative therapies, for example, against rare diseases. Proponents of bio-medicines also claim that precision therapy, because it is more efficient, will ease the burden on member states ailing healthcare systems.

The EBE suggests that steps should be taken to create a stronger investor community for biotech products to prevent places other than Europe from benefitting economically from technology invented and developed in Europe.

License to fail

The paper suggests that European entrepreneurs may be more adverse to risk because they have no license to fail, citing the lack of a strong culture of institutions or individuals seeking useful application of their work, taking out patents and creating start-up companies.

On the other hand, universities in the US often empower scientists to be knowledgeable in business and management.

The paper recommends that European institutions improve their support of scientists in marketing their technologies through better investment in Technical Transfer Offices (TTOs). The current lack of funding for TTOs at European universities means it is difficult for them to attract and train experienced staff.

Although Europe has public research funding organisations, such as the Innovative Medicines Initiative (IMI) and the European Commissions Horizon 2020, the lack of mature biotech companies makes the investment ecosystem fragile and makes it difficult for Europe to compete with the US for funding, the paper says.

Europe needs to build a bigger and better capital market for biotech companies to overcome the funding gap that prevents the needed growth of the biotech sector, it reads. The EBE suggests the European Commission create a single capital market for biotech companies and the creation of tax incentives for investment in biotechnology.

Being successful in the US

Didier Hoch, chairman of the Biovision 2017- The World Life Sciences Forum in Lyon, told EURACTIV that there are several reasons why biotechnology can flourish more easily in the US than in Europe.

According to Hoch, in terms of pure biotechnology, Europe is not lagging behind the US, as its sufficiently innovative. Where we are lagging behind is to drive investment in the field and attract private investors and open up the market to new products, he noted.

In fact, in the US the norm is to have a connection between the science, universities and private investors [] which is not yet the case in Europe, where there is a kind of fear when you are in the public sector to go private said Hoch, adding that another hindrance is the lack of trust between the public and private sector

Another difference between Washington and Brussels is the source of money. Hoch explained that money invested in the US biotech sector was coming from private investors, while in Europe, it comes from venture capital funds mainly funded by the EU institutions.

Even venture capitals are funded from EU money. This regime could eventually be thestrength for Europe, as in a way it can be competitive against private US money, he emphasised.

However, Hoch insisted that Europe still needed to convince more private sector entities to invest in biotechnology. It might be a long-term and risky field, but in the US the private sector invests in its potential, he said.

Hoch stressed that currently a biotech product could be considered successful if it has accessed the US market.

If you have a biotech company you should have in mind first to succeed in the US, even if you are based in Europe, he explained, explaining that in terms of the market, 70% of a new products success is in the US.

If you dont get your product there you will face difficulties, he said, emphasising that its mainly a political decision to have the US as an attracting market.

Last but not least, Hoch pointed out that its easier to get to the US market because there is a clear way to access and not like 27 different in the Europe, which have a country-based approach.

Making Europe innovative

In February, the centre-right European Peoples Party (EPP) presented its vision for the future of the Economic and Monetary Union (EMU) and emphasised the need for anew framework on access to financing in order for innovative companies to be encouraged to invest in Europe.

EPP President Joseph Daul told EURACTIV that the EU should become an innovation hub as this is the key to future growth and help it compete with the US.

This is where we need to concentrate our efforts to make Europe the worlds best talent hub. We should embrace radical innovations and make our continent the birthplace of the next Facebook or Apple, he told EURACTIV.

The EPP recognises that Europe was lagging behind compared to the US regarding innovative companies and, therefore, suggested the creation of an environment that will help new talents flourish.

We must understand that this follows partly from structural factors in our continent compared to our partners on the other side of the Atlantic. Venture Capital Funds in the EU are on average small. We need to support creating Funds of Funds, and we must look into existing regulations to make sure that investing in private equity funds is not discouraged by regulations and capital rules, the paper reads.

*Hannah Black contributed to this article.

See the article here:
Europe's biotechnology potential hindered by investment fears - EurActiv

Team chemistry key to Kilgore’s soccer success – Longview News-Journal

Posted on by

KILGORE It would be easy for David Garcia to look around the field and have a flashback.

It wouldn't be one just from this past season, but a memory from eight or more years ago.

"Since our rec teams, U-8, U-10, our team was called 'Little Mexico," Garcia, a four-year starter for the Kilgore Bulldogs, said. "We've got that chemistry with one another, eight years of it.

"It's not just the defense, this team has been together for a while."

Coupled with the long history of playing alongside one another has come a large amount of wins. Today marks the third-straight season that the Bulldogs will compete in the regional tournament.

Kilgore meets Dallas A Plus Academy at 4 p.m. today in a Class 4A, Region II semifinal at Tyler's Trinity Mother Frances Rose Stadium.

"We don't get down on one another and we've got great communication," fellow defender and senior Mateo Meraz said. "Four-straight defenders together on a team that we've been on since we played city league.

"That helps the chemistry."

Kilgore, which enters today with an 18-5-2 record, has a high-flying offense with 14 different goal scorers led by 18 each from sophomore Elian Torres and senior Yonatan Contreras and 14 different players with assists.

That offense is matched by the Bulldog defense with a back line of Garcia, Meraz, Jordi Contreras and Daniel Stifford who, alongside keeper Kaleb Jett have worked 11 shutouts on the season and four total goals through three playoff games.

"We just feed off another's energy," Meraz said. "It's a matter of matching one another and we've done that this season."

Added third-year head coach Austin Walker: "David and Mateo's leadership is excellent. Jordi has stepped into his role well and it's been a smooth transition for him. Daniel Stifford and Jaime Veloz have rounded out that back four, or when we drop five, making them very strong."

Not much is known about the Bulldogs' next opponent Dallas A Plus Academy, which took down Terrell, 1-0, in the regional quarterfinal round. The Knights come in with a 13-3 record and a 63-15 goals for/goals allowed mark.

"We don't know a lot about them," Walker said. "They tend to pack the middle and don't play outside as much, which is good for us because that's where we like to go.

"They're very physical and very high pressure all of the time. They're quick to press and like to get up in people's faces."

Kilgore enters today with momentum on its side having taken down defending state champion Palestine this past Tuesday with a convincing 4-2 win. It avenged a loss to the Wildcats this past season in a shootout in the state semifinals.

"I feel like we've been pretty focused for a few weeks now," Garcia said. "Palestine, they were a rival and we knew what we had to do.

"We beat them and now it's time to keep going."

Tuesday may as well be as far away as the state semifinal game a year ago.

"It really gave us a boost of confidence," Meraz added. "We've got a lot of momentum behind us with some great practices. It's going to to take us forward."

The goal, however, lies ahead of this coming weekend.

"We want to get back to where we've been," Walker said. "To do that, we've got to play this game right now.

"We can't let that Palestine win be a high point for us. Yes, it's exciting. Yes, we beat the team that knocked us out. There's more to be played and the job is not over yet."

CLASS 4A, REGION II TOURNAMENT

Christus Trinity Mother Frances Rose Stadium, Tyler

SEMIFINALS, TODAY

BOYS

Dallas A Plus Academy (13-3) vs. Kilgore (18-5-2), 4 p.m.

Irving Ranchview (19-1-1) vs. Chapel Hill (16-7-1), 6:30 p.m.

FINAL, SATURDAY

Semifinal winners, 1:30 p.m.

GIRLS

SEMIFINALS, TODAY

Mabank (19-5) vs. Athens (14-10-1), 11 a.m.

Terrell (23-5) vs. Palestine (16-7-5), 1:30 p.m.

FINAL, SATURDAY

Semifinal winners, 11 a.m.

Read this article:
Team chemistry key to Kilgore's soccer success - Longview News-Journal

Student to represent Wisconsin in national chemistry competition – Lake Country Now

Posted on by

Subscribe today for full access on your desktop, tablet, and mobile device.

Let friends in your social network know what you are reading about

An eighth-grader from Oconomowoc won a statewide chemistry competition and received an expenses-paid trip to compete at the national level.

Try Another

Audio CAPTCHA

Image CAPTCHA

Help

CancelSend

A link has been sent to your friend's email address.

A link has been posted to your Facebook feed.

Lake Country 1:31 p.m. CT April 6, 2017

School brief(Photo: Matt Colby/Now Media Group)Buy Photo

An eighth-grader from Oconomowoc won a statewide chemistry competition and received an expenses-paid trip to compete at the national level.

Ryan Swanson, a student at Nature Hill Intermediate School, bested 25 fifth- to eighth-grade students to become the 2017 Wisconsin You Be The Chemist State Challenge Champion. Students from around the state came together at the University of Wisconsin-Madison to compete for the top prize. Swanson will represent Wisconsin at the National You Be The Chemist Challengein Washington, D.C. in June.

Read or Share this story: http://www.lakecountrynow.com/story/news/local/oconomowoc-focus/2017/04/06/student-represent-wisconsin-national-chemistry-competition/100127738/

0) { %>

0) { %>

Follow this link:
Student to represent Wisconsin in national chemistry competition - Lake Country Now

Grey’s Anatomy recap: ‘What’s Inside’ – EW.com

Posted on by

Have you stopped crying from last week? Me neither. Neither have your regular recappers, who are out this week, but in their stead, I take onGreys Anatomy with you Youre in trusted hands because I pick you, I choose you, I love you. I dont need to loveGreys, but I want to, and sometimes I cant think about the bigger picture because Ive lost my shoe. But well all pull it together this week because in the wake of losing her mother, Maggie needs us. Shes about to join a sacredGreys club.

Its finally time for the last sister to become twisted. After losing her mom last week, we open with Maggie at her mothers grave a concept foreign to Mer and Amelia because you know, dark and twisty hall of fame. Amelia has her oxycodone background and Meredith has, well, everything. But after the graveyard, its time for Maggies first day back.

Riggs catches Arizona and Mennick carpooling in together, which is what it is. We turn a blind eye to Mennick because there are bigger fish to fry. Example: Arizonas pregnant patient, whom she placed a shunt in last week. No matter how much Arizona wants to make a point that she and Mennick werent justcarpooling in together, her patients heart surgery is more complicated than matters of the bedroom. Maggie hears about it and immediately wants in because thats what surgeonsdo when tragedy happens: cut stuff. But this is Dr. Herman fetal surgery-level serious, and not everyone is so sure shes ready for it. And when the patient overhears that maybe Maggie shouldnt be taking it on, they want answers.

Stephanie is stuck with Cross, and honestly, she has no time for it. Its what makes Stephanie wonderful. She calls in DeLuca to try to shame Cross into getting out of bed, but when he protests that hes actually sick, Stephanie goes to step two: rectal exam. But after landing himself in an MRI, it does appear that Cross has a point after all. He has diverticulitis, an annoyed Stephanie is going to operate, and you can only think with a case so simple, thiscant go well, right?

Poor Meredith has little knowledge of when someone is okay or not okay. Its a symptom of being kind of twisted your whole life. And when everyone believes that maybe Maggie needs a break, Meredith argues otherwise because she operated through a miscarriage remember? Yikes. But after enough pushing, Amelia and Meredith try to question Maggie on whether or not shes ready, and she doesnt love it at all because today is her day. Her First Day Back From Dead Mom Day, and theyre not there for her, yall! But Maggie goes into surgery with Arizona, who asks her one last time if shes okay because this is tiny humans, and shehas to be on for the tiny humans. But after removing the tumor like a complete boss, Maggie freezes when the baby starts coding. What needs to be done? Who knows Maggie isnt talking.

Read the original here:
Grey's Anatomy recap: 'What's Inside' - EW.com

Former Sen. David Vitter lobbying for American Chemistry Council – Washington Examiner

Posted on by

Former Sen. David Vitter, R-La., is now lobbying for a trade association for chemical companies.

According to a lobbying registration form, Vitter registered to lobby for the American Chemistry Council on March 15. His employer is Mercury, a lobbying and public relations firm he joined in February.

ACC was a major donor supporting Vitter. The group gave more than $100,000 to a super PAC backing his failed gubernatorial run in 2014. Vitter retired from Congress when his Senate term was up in January.

Vitter currently cannot lobby his former congressional colleagues, as he is subject to a two-year "cooling-off period," but he can lobby the Trump administration.

As senator, Vitter was leading figure in getting bipartisan legislation on chemical regulation reform passed an effort supported by ACC. The Frank R. Lautenberg Chemical Safety for the 21st Century Act updated the Toxic Substances Control Act which was passed in 1976. Former President Barack Obama signed the bill last year.

ACC did not immediately return a request for comment.

Continue reading here:
Former Sen. David Vitter lobbying for American Chemistry Council - Washington Examiner

Affordable, Entry-level Flow Chemistry Systems – Technology Networks

Posted on by

Available in a choice of configurations the Uniqsis FlowLab range are affordable and easy-to-use flow chemistry systems ideal for use in research, education and for those wishing to try flow chemistry without the associated costs of a fully automatic system.

Built around the same high quality components as used in the widely acclaimed Uniqsis FlowSyn system, both the FlowLab and FlowLab Cold offer uncompromised performance at an entry-level price.

The FlowLab system comprises two high pressure pumps, a HotCoil coil reactor station and FlowLab system control computer. The computer, pumps and HotCoil are connected over a LAN using an Ethernet hub. In this way, the system can be controlled remotely by Wi-Fi, allowing the control computer to be conveniently operated outside the fume hood. FlowLab Cold includes the Polar Bear Plus Flow module which provides cooling down to -40C without the need for liquid nitrogen or solid carbon dioxide (Cardice).

The system can be further adapted using HotColumn which can accommodate up to six column reactors for catalysts or scavenging applications, or in the case of FlowLab Cold, fitted with a static reactor/mixer chip holder. In addition, there are options to add a third HPLC pump and a second reactor module such as a HotCoil or Polar Bear Plus Flow which together provide an operating temperature range of - 40C to +300C. An optional inline Flow-UV detector can also be included to monitor dispersion and help to determine the optimum point at which to begin and end product collection.

FlowLab application software provides control of the system via a step-through interface that can be learnt in minutes and is highly intuitive to use. Programs can be designed and saved reactions run automatically, including priming and washing. The program is monitored on a real time display showing temperatures and pressures. FlowLab also automatically detects any modules that have been added to the system.

Like what you just read? You can find similar content on the communities below.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

See the original post:
Affordable, Entry-level Flow Chemistry Systems - Technology Networks

Biotechnology in Iran – Press TV

Posted on by

Iran has made a considerable breakthrough in biotechnology inasmuch as it is able to produce GM foods and Up until 2013 it has produced 18 different kinds of recombinant medicines.

The modern biotechnology has been established nearly nine decades ago in Iran, started with vaccine production in Pasteur and Razi Institutes in 1920 and 1925. National Institute of Genetic Engineering and Biotechnology institute of Iran was established in 1989. Iranian scientists are active in various spheres of agriculture in this institute and work on medicinal plants with the aim of using their metabolites or increasing their tolerance to non-biological changes such as salinity or drought. One of the uses of biotechnology is in production of genetically modified foods; however, there are many opposing voices claiming that they are harmful for health.

Simply said, biotechnology harnesses cellular and bi molecular processes and puts them to work for us. It is used for production of GM foods and treating diseases with genetic technologies and many other fields. Biotechnology is an efficient, up-to-date and effective tool in agricultural field. Biotechnology helps you to improve plants' resistance to a considerable amount. Iran is among pioneering countries in this field. Up until 2013, 18 different kinds of recombinant drugs have been produced in Iran. This number is against 50 recombinant drugs produced globally. With the help of biotechnology and recombinant drugs, Iran has seen a 30% drop in its drug export and 50% inflation growth has been controlled.

Link:
Biotechnology in Iran - Press TV

Innovative Sensor Can Screen Toxic Drugs, Help Develop Biomaterials, and Much More – UCR Today (press release)

Posted on by

UCR researchers used glass tubing and off-the-shelf electronics to create an inexpensive sensor that can weigh microgram-sized biological samples in fluids

By Sarah Nightingale on April 5, 2017

A glass tube sensor developed by engineers at the University of California, Riverside will allow scientists to weigh tiny biological samples in their native liquid environments.

RIVERSIDE, Calif. (www.ucr.edu) Researchers at the University of California, Riverside have found an innovative new use for a simple piece of glass tubing: weighing things. Their glass tube sensor will help speed up chemical toxicity tests, shed light on plant growth, and develop new biomaterials, among many other applications.

The research, led by William Grover, assistant professor of bioengineering in UC Riversides Bourns College of Engineering, and Shirin Mesbah Oskui, a doctoral student in Grovers lab who recently graduated, was published today in the journal PLOS ONE. The paper describes the development of a simple, inexpensive sensor to measure the mass, volume, and density of microgram-sized biological samples in fluid. The research has important applications in toxicity research as well as many other areas, including developmental biology, plant sciences, and biomaterials engineering.

While weight is one of the most fundamental and important measures of an object, weighing tiny biological samples in their native liquid environments is not possible with conventional scales. To change that, Mesbah Oskui developed a sensor comprising a small piece of glass tubing bent into a U shape and attached to an inexpensive speaker. The speaker vibrates the glass at its resonance frequency, which is a function of the overall mass of the tube. When a sample is pumped into the tube, the resonance frequency changes, allowing the samples mass, density and volume to be calculated. The research expands a technique originally developed at MIT for weighing single cells. By opening this technique to larger samples, the research vastly increases its applications.

As proof of concept, the researchers turned to an important research area: toxicology. Many chemicals in use today are yet to be fully evaluated for their risk to human health and the environment, primarily because toxicology tests on traditional animal models are expensive, time consuming and labor-intensive. While the introduction of tests using tiny, fast-developing zebrafish embryos is speeding things up, until now, scientists havent been able to weigh the embryos in their native fluid environment. In the paper, the researchers used the sensors to measure mass changes in zebrafish embryos as they reacted to toxic silver nanoparticles.

Left to right: William Grover, assistant professor of bioengineering at UCR, Shirin Mesbah Oskui, who recently completed her Ph.D. in bioengineering, and Heran Bhakta, a graduate student in bioengineering.

Zebrafish embryos are becoming an important toxicological model species, but until now scientists have not been able to include a very simple measure of healththe organisms weightin their panel of measurements. Our research changes that, which will further expand the use of this model in helping protect human health and the environment, Mesbah Oskui said.

Also in the paper, the researchers described using the sensor to measure density changes in seeds undergoing rehydration and germination, and degradation rates of biomaterials used in medical implants. Heran Bhakta, a graduate student in bioengineering, led the work on biomaterials degradation.

Biodegradable materials can be used to cover a wound after surgery, but if they degrade too quickly they can leave an open wound and if they dont degrade quickly enough they can cause complications, Bhakta said. Previously, tracking the degradation of biomaterials in a fluid environment has been a painstaking and error-prone process in which the biomaterial sample must be removed, cleaned, weighed and replaced on an ongoing basis. In contrast, our sensors enable us to measure the degradation of even the tiniest biomaterials samples continuously as they break down in a biological fluid, Bhakta said.

Grover said the automation, portability and low cost of the technique make the sensors well suited for applications in the field or in resource-limited settings.

Our technique is so versatile because all objects have fundamental properties like weight. I am excited to see how the sensors will be used by other researchers to address scientific problems in many other fields, he said.

In addition to Grover, Mesbah Oskui and Bhakta, other contributors included Graciel Diamante, a graduate student in environmental sciences; Huinan Liu, associate professor of bioengineering; and Daniel Schlenk, professor of aquatic ecotoxicology, all at UC Riverside.

Archived under: Science/Technology, bioengineering, Bourns College of Engineering, Department of Bioengineering, press release, William Grover

Top of Page

More here:
Innovative Sensor Can Screen Toxic Drugs, Help Develop Biomaterials, and Much More - UCR Today (press release)

Adkins admits emailing photos of male anatomy | Local News | The … – The News (subscription)

Posted on by

The day before law enforcement arrested the Rev. Kenneth Adkins in August 2016, he admitted to Georgia Bureau of Investigators agents he sent photos of his male anatomy to a man hes accused of molesting when that person was underage.

Adkins is on trial in Glynn County Superior Court regarding multiple felonies for allegedly engaging in sexual acts with two victims A.J., a boy, and T.V., a girl when they were both 15 years old, between August 2009 and March 2010.

Prosecutors played for the jury a recording of the GBIs interview with Adkins, in which after a friendly back-and-forth, the agents began pressing Adkins for clearer answers on his involvement with evidence they already had in hand.

At one point, they specifically questioned his involvement with two photographs of a black males private parts sent from Adkins public relations companys email account to A.J. in November 2014.

One agent could be heard saying, I know it was sent from your phone to your email to (A.J.).

Adkins then said he only sent the photos because A.J. asked for them. That also occurred well after A.J. reached majority age, and Adkins reiterated that he did not mess around with children.

Lawrence Kelly, a special agent with the GBI who specializes in mobile phone data forensics, said metadata pulled from the emailed images showed they were sent from a Samsung Galaxy Note 4, operating on a Verizon network. The data also showed the phone was registered the day before the images were sent, which means the phone was likely, but not conclusively, obtained the day it was registered.

When questioned by Adkins attorney Kevin Gough if it was possible Adkins could have sent the photos accidentally, Kelly said it was. Kelly also acknowledged that the timestamps of when the email was sent and received indicated that, as Gough suggested in a question, it was sent from Georgia and received by A.J. while on Army deployment in Germany.

A contention made by prosecutors is the photos indicate a physical relationship between Adkins and A.J., though Kelly admitted it would be rather difficult to have a physical relationship at that immediate time, separated by an ocean.

According to investigators, one woman, J.C. who was of age at the time told them she, A.J. and Adkins engaged in sexual acts at an area hotel, though she was initially reluctant to do so. Adkins allegedly warned her about saying anything about it, and gave her $200 to remain quiet.

In the GBI interview, Adkins, at first, denied getting a room for A.J. or the three of them, saying he frequently reserved rooms for any number of functions. But, again, pressed on the topic, Adkins said, I dont think I was in the room with A.J. and J.C., and reiterated that he did not have sex with them.

At the end of testimony Tuesday, the defense had to wrap up one of the basic logistics of trial work not typically seen by the public Adkins had run out of ties. Gough asked Superior Court Judge Stephen Scarlett if he could give his client his own tie, but after a short discussion in which the participants appeared to understand the light humor of the situation in comparison to those of such gravity beforehand Gough was allowed to take the necessary sartorial items to Adkins at the Glynn County Detention Center during a meeting scheduled for later Tuesday.

Court is scheduled to resume with testimony by A.J. at 9 a.m. today at the Glynn County Courthouse.

The rest is here:
Adkins admits emailing photos of male anatomy | Local News | The ... - The News (subscription)

NKPD1 gene variant increases depression risk – Medical Xpress

Posted on by

April 4, 2017 Credit: George Hodan/Public Domain

A study of people from an isolated village in the Netherlands reveals a link between rare variants in the gene NKPD1 and depressive symptoms. The findings are published in the current issue of Biological Psychiatry. The study, led by co-first authors Najaf Amin, PhD, of Erasmus University Medical Center in the Netherlands and Nadezhda Belonogova of the Russian Academy of Sciences in Novosibirsk, Russia, helps researchers understand the molecular pathology of the disease, which could eventually improve how depression is diagnosed and treated.

Genetics play a strong role in risk for depression, but the identification of specific genes contributing to the disorder has eluded researchers. "By sequencing all of the DNA that codes for mRNA and ultimately, proteins, Dr. Amin and colleagues found a single gene that may account for as much as 4% of the heritable risk for depression," said Doctor John Krystal, Editor of Biological Psychiatry.

To identify the gene, the researchers assessed data from the Erasmus Rucphen Family study, which was composed of a collection of families and their descendents living in social isolation until the past few decades. In a population like this, genetic isolation leads to an amplification of rarely occurring variants with little other genetic variation, providing a more powerful cohort for the discovery of rare variants. Nearly 2,000 people who had been assessed for depressive symptoms were included in the analysis.

Using whole-exome sequencing to examine portions of DNA containing genetic code to produce proteins, Amin and colleagues found that several variants of NKPD1 were associated with higher depressive symptom scores. The association between depressive symptoms and NKPD1 were also replicated in an independent sample of people from the general population, although the replication sample highlighted different variants within NKPD1.

"The involvement of NKPD1 in the synthesis of sphingolipids and eventually of ceramides is interesting," said Dr. Amin, referring to the predicted role of NKPD1 in the body. Altered sphingolipid levels in blood have been associated with depression and have been proposed as a therapeutic target for major depressive disorder.

"We are the first to show a possible genetic connection in this respect," said Dr. Amin, adding that this implies that such a therapy might be beneficial for patients carrying risk variants in the NKPD1 gene.

As with other psychiatric disorders, depression lacks genetic or biochemical markers to aid diagnosis and treatment of the disorder. According to Dr. Amin, moving depression treatment into the era of precision and personalized medicine will require a transition to objective and unbiased measurements where patients are stratified based on the molecular pathology of the disease. "NKPD1 may be one such molecular mechanism," she said.

Explore further: Earlier and more severe depression symptoms associated with high genetic risk for major psychiatric disorders

More information: Najaf Amin et al. Nonsynonymous Variation inNKPD1Increases Depressive Symptoms in European Populations, Biological Psychiatry (2017). DOI: 10.1016/j.biopsych.2016.08.008

Journal reference: Biological Psychiatry

Provided by: Elsevier

Clinical features of major depressive disorder (MDD) may help identify specific subgroups of depressed patients based on associations with genetic risk for major psychiatric disorders, reports a study in Biological Psychiatry. ...

An international group of more than 190 scientists who analyzed the genomes of 298,420 individuals have found genetic variants that may influence our sense of wellbeing, depression and neuroticism.

Antidepressants are commonly prescribed for the treatment of depression, but many individuals do not experience symptom relief from treatment. The National Institute of Mental Health's STAR*D study, the largest and longest ...

Depression symptoms that steadily increase in older adults are more strongly linked to dementia than any other types of depression, and may indicate the early stages of the disease, according to the first ever long-term study ...

(Medical Xpress)A very large team of researchers made up mostly of members in China and calling itself the CONVERGE consortium, has identified two genetic variants that appear to be associated with major depressive disorder ...

New research findings often garner great attention. But when other scientists follow up and fail to replicate the findings? Not so much.

How often do you act impulsively without considering the consequences? What if you could learn how to be more patient?

Scientists at the University of Basel have shown that LSD reduces activity in the region of the brain related to the handling of negative emotions like fear. The results, published in the scientific journal Translational ...

Scientists at the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health are the first to report immune signatures differentiating two subgroups of myalgic encephalomyelitis/chronic ...

The common antibiotic doxycycline can disrupt the formation of negative associations in the brain, according to new research from UCL and the University of Zurich.

A study of people from an isolated village in the Netherlands reveals a link between rare variants in the gene NKPD1 and depressive symptoms. The findings are published in the current issue of Biological Psychiatry. The study, ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Continued here:
NKPD1 gene variant increases depression risk - Medical Xpress

Screening the dark genome for disease – Science Daily

Posted on by

Researchers have developed a method to swiftly screen the non-coding DNA of the human genome for links to diseases that are driven by changes in gene regulation. The technique could revolutionize modern medicine's understanding of the genetically inherited risks of developing heart disease, diabetes, cancer, neurological disorders and others, and lead to new treatments.

The study appeared online in Nature Biotechnology on April 3, 2017.

"Identifying single mutations that cause rare, devastating diseases like muscular dystrophy has become relatively straightforward," said Charles Gersbach, the Rooney Family Associate Professor of Biomedical Engineering at Duke University. "But more common diseases that run in families often involve lots of genes as well as genetic reactions to environmental factors. It's a much more complicated story, and we've been wanting a way to better understand it. Now we've found a way."

The new technique relies on the gene-hacking system called CRISPR/Cas9. Originally discovered as a natural antiviral defense mechanism in bacteria, the system recognizes and homes in on the genetic code of previous intruders and then chops up their DNA. In the past several years, researchers have harnessed this biologic system to precisely cut and paste DNA sequences in living organisms.

In the current study, researchers added molecular machinery that can control gene activity by manipulating the web of biomolecules that determines which genes each cell activates and to what degree.

With the new tool, Gersbach and his colleagues are exploring the 98 percent of our genetic code often referred to as the "dark matter of the genome."

"Only a small fraction of our genome encodes instructions to make proteins that guide cellular activity," said Tyler Klann, the biomedical engineering graduate student who led the work in Gersbach's lab. "But more than 90 percent of the genetic variation in the human population that is associated with common disease falls outside of those genes. We set out to develop a technology to map this part of the genome and understand what it is doing."

The answer, says Klann, lies with promoters and enhancers. Promoters sit directly next to the genes they control. Enhancers, however, which modulate promoters, can be just about anywhere due to the genome's complex 3D geometry, making it difficult to discern what they're actually doing.

"If an enhancer is dialing a promoter up or down by 10 or 20 percent, that could logically explain a small genetic contribution to cardiovascular disease, for example," said Gersbach. "With this CRISPR-based system, we can more strongly turn these enhancers on and off to see exactly what effect they're having on the cell. By developing therapies that more dramatically affect these targets in the right direction, we could have a significant effect on the corresponding disease."

That's all well and good for exploring the regions of the genome that researchers have already identified as being linked to diseases, but there are potentially millions of sites in the genome with unknown functions. To dive down the dark genome rabbit hole, Gersbach turned to colleagues Greg Crawford, associate professor of pediatrics and medical genetics, and Tim Reddy, assistant professor of bioinformatics and biostatistics. All three professors work together in the Duke Center for Genomic and Computational Biology.

Crawford developed a way of determining which sections of DNA are open for business. That is, which sections are not tightly packed away, providing access for interactions with biomachinery such as RNA and proteins. These sites, the researchers reason, are the most likely to be contributing to a cell's activity in some way. Reddy has been developing computational tools for interpreting these large genomic data sets.

Over the past decade, Crawford has scanned hundreds of types of cells and tissues affected by various diseases and drugs and come up with a list of more than 2 million potentially important sites in the dark genome -- clearly far too many to investigate one at a time. In the new study, Crawford, Reddy and Gersbach demonstrate a high-throughput screening method to investigate many of these potentially important genetic sequences in short order. While these initial studies screened hundreds of these sites across millions of base pairs of the genome, the researchers are now working to scale this up 100- to 1000-fold.

"Small molecules can target proteins and RNA interference targets RNA, but we needed something to go in and modulate the non-coding part of the genome," said Crawford. "Up until now, we didn't have that."

The method starts by delivering millions of CRISPR systems loaded into viruses, each targeting a different genetic point of interest, to millions of cells in a single dish. After ensuring each cell receives only one virus, the team screens them for changes in their gene expression or cellular functions.

For example, someone researching diabetes could do this with pancreatic cells and watch for changes in insulin production. Those cells that show interesting alterations are then isolated and sequenced to determine which stretch of DNA the CRISPR affected, revealing a new genetic piece of the diabetes puzzle.

The technique is already producing results, identifying previously known genetic regulatory elements while also spotting a few new ones. The results also showed it can be used to turn genes either on or off, which is superior to other tools for studying biology which only turn genes off. Different cell types also produced different -- but partially overlapping -- results, highlighting the biological complexity in gene regulation and disease that can be interrogated with this technology.

"Now that we have this tool, we can go in and annotate the functions of these previously unknown but important stretches of our genome," said Gersbach. "With so many places to look, and the ability to do it quickly and robustly, we'll undoubtedly find new segments that are important for disease, which will provide new avenues for developing therapeutics."

See the article here:
Screening the dark genome for disease - Science Daily

Skeletons developed as chemistry of oceans changed, study shows – Astrobiology Magazine (registration)

Posted on by

Fieldwork at the Yudoma River in Siberia, Russia. Credit: Rachel Wood

Skeletons and shells first came into being 550 million years ago as the chemical make-up of seawater changed, a study suggests.

Ancient marine life may have developed from soft-bodied animals into creatures with hard body parts as oxygen levels rose and calcium and magnesium levels in prehistoric oceans changed, researchers say.Until now, little was known about how skeletons and shells which are made of calcium carbonate first evolved, the team says.

Previous theories suggested that soft-bodied organisms had undergone a mass extinction, which allowed organisms with skeletons and shells to flourish.However, researchers at the University of Edinburgh have found that the earliest lifeforms with hard body parts co-existed with closely related soft-bodied species.

The team examined a range of fossils unearthed from limestone rocks in Siberia, which formed millions of years ago from seawater with high levels of calcium carbonate.They concluded that hard-bodied lifeforms were first present only in such environments where high levels of calcium carbonate allowed organisms to develop primitive hard parts.

Artists impression of a Suvorevella fossil, one of the oldest known skeletal macrofossils. Credit: Alina Konovalenko

Around 10m years later, the diversity of life of Earth increased rapidly a period known as the Cambrian explosion and hard-bodied life began to thrive. An increased threat from predators led lifeforms to develop new, more complex hard parts in environments that were less carbonate-rich, the team says.

The development of hard body parts through a process called biomineralisation marked a significant evolutionary advance from the previous world of soft-bodied life, the team says.

The study is published in the journal Proceedings of the Royal Society B. The research was carried out in collaboration with Lomonosov Moscow State University.

Professor Rachel Wood, of the University of Edinburghs School of GeoSciences, who led the study, said: How animals produced shells and skeletons is one of the major events in the evolution of life. We are only now starting to understand the processes underlying this revolution.

Original post:
Skeletons developed as chemistry of oceans changed, study shows - Astrobiology Magazine (registration)

Sugar Chemistry Is Helping Zika Virus Cross The Placenta – Forbes

Posted on by

Forbes
Sugar Chemistry Is Helping Zika Virus Cross The Placenta
Forbes
Remember Zika virus? It might not be popping up in your news feed or your searches lately. But that shouldn't necessarily be reassuring. Yes, the World Health Organization lifted its emergency declaration on Zika in November. When they did, though ...
Stopping Zika from crossing the placenta American Chemical SocietyEurekAlert (press release)

all 29 news articles »

See the article here:
Sugar Chemistry Is Helping Zika Virus Cross The Placenta - Forbes

Bipartisan Lawmakers Announce Senate Chemistry Caucus – Chem.Info

Posted on by

Eight senators last week announced the formation of a new group to assess issues related to chemistry and the nation's chemical sector.

The Senate Chemistry Caucus, members said, would provide a bipartisan forum to discuss chemistry and its economic impacts, as well as facilitate policies that encourage science education and innovation in chemical manufacturing.

The group will be helmed by co-chairs Chris Coons, D-Del., Gary Peters, D-Mich., Shelley Moore Capito, R-W.V. -- whose states are home to major chemical companies, including DuPont and Dow and Steve Daines, R-Mont. and a chemical engineer by trade.

We cant predict what the next big thing will be, but every day the field of chemistry is making groundbreaking discoveries that can grow our economy and improve our daily lives," Peters said in a statement. "Im proud to help launch the bipartisan Senate Chemistry Caucus to encourage scientific research, spur new innovation and promote safety in the chemical industry.

Other members include John Boozman, R-Ark., John Neely Kennedy, R-La., Joe Donnelly, D-Ind., and Joe Manchin, D-W.V.

The Senate caucus follows a House chemistry caucus founded last summer by Reps. John Moolenaar, R-Mich., and Daniel Lipinski, R-Ill. The Congressional Chemistry Caucus now has more than 35 members.

Chemical industry groups lauded the formation of the caucus at "a very pivotal moment for the chemical industry and manufacturing."

Read more:
Bipartisan Lawmakers Announce Senate Chemistry Caucus - Chem.Info

DevonWay Inc. Expands into Biotechnology Industry – Yahoo Finance

Posted on by

SAN FRANCISCO--(BUSINESS WIRE)--

DevonWay, Silicon Valleys leading provider of continuous improvement software to large enterprises, announced today its expansion into a new industry with the adoption of a global, Fortune 500 biotechnology client.

Biotechs emphasis on safety, quality, reliability, and innovation make it a natural fit for DevonWay software, which is in widespread use by global construction companies, utilities, and government agencies.

Its an exciting time to be a part of biotech, said DevonWay CEO Chris Moustakas, and were thrilled to serve an industry that has such a huge impact on public health, disease prevention, and treatment. One of the challenges facing biotech today is maintaining a culture of innovation, which feeds the industrys rapid growth, while never sacrificing quality or safety. Were grateful for the opportunity to help the industry meet this challenge head-on.

Although many biotechnology companies use Quality Management Systems to help ensure quality and regulatory compliance, those systems often lack the flexibility needed to handle specific operational requirements. Continuous improvement software, such as that provided by DevonWay, is purpose-built to bridge the gap between operations and quality, and can serve the needs of both in a single closed-loop, FDA 21CFR11-compliant system.

Whether were brought on board to complement an existing QMS or outright replace it, our first and foremost priority is to serve the needs of our customers, says Matt Sacks, DevonWays Vice President of Sales. Unlike most systems currently servicing life sciences, our products can evolve without having to modify code. In an industry in which change is constant, this ability to facilitate change quickly and cost effectively provides a crucial advantage to our customers.

About DevonWay

Founded in San Francisco in 2005, DevonWay is a leading provider of continuous improvement and digital operations applications to customers across industries as diverse as energy generation, transmission and distribution, government, life sciences, and construction. By combining flexibility with ease of use, DevonWay helps high-reliability organizations transform, digitize, and continuously improve their operations.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170404006173/en/

Originally posted here:
DevonWay Inc. Expands into Biotechnology Industry - Yahoo Finance

Puma Biotechnology (PBYI) Highlights Interim Results of Phase II CONTROL Trial of PB272 at AACR Meetings – StreetInsider.com

Posted on by

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Puma Biotechnology, Inc. (NASDAQ: PBYI) announced that interim results from a Phase II clinical trial of Pumas investigational drug PB272 (neratinib) were presented at the 2017 American Association for Cancer Research Annual Meeting (AACR) that is currently taking place in Washington, D.C. The presentation, entitled Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2-positive early stage breast cancer: the CONTROL trial, was presented as a poster presentation.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170404005596/en/

The main adverse event that has been seen to date in clinical trials of neratinib is diarrhea and more specifically grade 3 diarrhea. In the Phase III ExteNET trial of neratinib as extended adjuvant treatment of HER2-positive early stage breast cancer that has previously been treated with adjuvant Herceptin, 95.4% of the patients experienced all grade diarrhea and 39.8% of the patients experienced grade 3 or higher diarrhea (there was one event of grade 4 diarrhea). The CONTROL trial is an international, open-label, Phase II study investigating the use of loperamide prophylaxis with or without other agents in the reduction of neratinib-associated diarrhea that has a primary endpoint of the incidence of grade 3 diarrhea.

In the CONTROL trial, patients with HER2-positive early stage breast cancer who had completed trastuzumab-based adjuvant therapy received neratinib daily for a period of one year. High dose loperamide prophylaxis was given for the first 2 cycles (56 days) of treatment. Initially, the loperamide dosing used was 16 mg on day 1, then 12 mg on days 2 and 3 and then 6-8 mg on days 4-56 (original dosing). The protocol was later amended to simplify the regimen such that patients took 12 mg on days 1-14 and 8 mg on days 15-56 (modified dosing). The CONTROL trial was also expanded to include two additional cohorts. One cohort received the combination of loperamide and budesonide and the other cohort received the combination of loperamide plus colestipol. Budesonide is a locally acting corticosteroid that the Company believes targets the inflammation identified in a preclinical model of neratinib-induced diarrhea and colestipol is a bile acid sequestrant that the Company believes targets the bile acid malabsorption also seen in preclinical models of neratinib-induced diarrhea.

The interim analysis of the trial presented in the poster included a total of 137 patients who received neratinib plus loperamide prophylaxis (28 patients taking the original dosing and 109 patients taking the modified dosing), 64 patients who received neratinib plus loperamide prophylaxis for 2 cycles and budesonide for 1 cycle, and 26 patients who received neratinib plus loperamide prophylaxis for 1 cycle and colestipol for 1 cycle.

The results of the trial showed that the incidence of grade 3 diarrhea for the 137 patients who received the loperamide prophylaxis was 30.7%. For the 137 patients who received the loperamide prophylaxis, the median number of grade 3 diarrhea episodes per patient was 1 and the median cumulative duration of grade 3 diarrhea was 3 days. For the 137 patients who received loperamide prophylaxis, 20.4% discontinued neratinib due to diarrhea.

For the 64 patients who received the combination of loperamide plus budesonide, the results of the trial showed that the incidence of grade 3 diarrhea was 23.4%. The median number of grade 3 diarrhea episodes per patient was 1 and the median cumulative duration of grade 3 diarrhea was 2 days. For the 64 patients who received loperamide plus budesonide prophylaxis, 9.4% discontinued neratinib due to diarrhea.

For the 26 patients who received the combination of loperamide plus colestipol, the results of the trial showed that the incidence of grade 3 diarrhea was 11.5%. The median number of grade 3 diarrhea episodes per patient was 2 and the median cumulative duration of grade 3 diarrhea was 2 days. For the 26 patients who received loperamide plus colestipol prophylaxis, no patient (0%) discontinued neratinib due to diarrhea. Further information is provided in Table 1 below:

Table 1: Characteristics of Treatment-Emergent Diarrhea

Loperamide

(original +

modified)

loperamide

loperamide

Loperamide

prn

a

In the ExteNET trial, higher grade (grade 2 and grade 3) diarrhea occurred early and persisted throughout the duration of the 12-month treatment period. In the CONTROL trial, in the loperamide prophylaxis, loperamide plus budesonide prophylaxis and loperamide plus colestipol prophylaxis arms, the results showed that higher grade diarrhea (grades 2 and 3) occurred early but did not typically recur. This is shown in more detail in Figure 1: Treatment Emergent Diarrhea, which is attached to this news release. In addition, a full copy of the poster that was presented at AACR is available on the Puma Biotechnology website.

During the course of the CONTROL trial there has been an increase in the proportion of patients previously treated with pertuzumab (mainly in the neoadjuvant setting). For the 55 patients in the loperamide prophylaxis cohort who received prior pertuzumab, the grade 3 diarrhea rate was 38.2% (Table 2). For the 82 patients who did not receive prior pertuzumab, the grade 3 diarrhea rate was 25.6%. For the 39 patients in the budesonide cohort who received prior pertuzumab, the grade 3 diarrhea rate was 10.3%. For the 25 patients in the budesonide cohort who did not receive prior pertuzumab, the grade 3 diarrhea rate was 36.0%. This analysis suggests that prior pertuzumab exposure may have led to a higher rate of grade 3 diarrhea in the CONTROL trial that was not effectively managed by loperamide prophylaxis alone but was more effectively managed by loperamide plus budesonide.

Table 2: Incidence of Grade 3 Diarrhea in CONTROL by Prior Pertuzumab Treatment

Loperamide Cohort

Budesonide Cohort

(n = 55)

(n = 82)

(n = 39)

(n = 25)

Dr. Carlos H. Barcenas, Assistant Professor, Department of Breast Medical Oncology and Associate Medical Director, Breast Cancer Survivorship Clinic for the University of Texas MD Anderson Cancer Center, said, We are pleased to see the reduction in incidence, severity and duration of neratinib-associated diarrhea when using the three antidiarrheal prophylaxis regimens tested so far in this study. When using either the loperamide prophylaxis, the loperamide plus budesonide prophylaxis or the loperamide plus colestipol prophylaxis, there appears to be a reduction in the incidence and severity of grade 3 diarrhea with neratinib. Importantly, the severe grade 2 and grade 3 diarrhea, when using the prophylaxis, appears to be acute, self-limiting and manageable. Although the study is still ongoing, we are encouraged that the addition of budesonide or colestipol appears to greatly improve the tolerability of neratinib as well. We look forward to completing the loperamide plus colestipol cohort.

Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology, said, We are pleased to see the reductions in the incidence of severe neratinib-related diarrhea in the CONTROL trial when using the loperamide, loperamide plus budesonide or loperamide plus colestipol regimens. The severe diarrhea appears to become more acute, whereby it does not typically recur after the first month. We are also very encouraged by the improvements in tolerability that have been seen to date in the budesonide and the colestipol cohorts. This is a marked improvement in tolerability over what was seen in the ExteNET trial and we look forward to continuing to monitor this in the loperamide plus colestipol cohort.

Read more here:
Puma Biotechnology (PBYI) Highlights Interim Results of Phase II CONTROL Trial of PB272 at AACR Meetings - StreetInsider.com

Cellect Biotechnology (APOP) Jumps: Stock Moves 10.5% Higher – Zacks.com

Posted on by

by Zacks Equity Research Published on April 04, 2017

ANTH APOP

Cellect Biotechnology Ltd. (APOP - Free Report) was a big mover last session, as the company saw its shares rise over 10% on the day. The move came after the company announced that it has received a formal notice of Intention to Grant for a patent covering a key method of treatment from the European Patent Office. This also led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.94 to $10.90 in the past one-month time frame.

None of the estimates for this stock were revised in the last 30 days and the Zacks Consensus Estimate also remained unchanged. Yesterdays price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Currently, Cellect Biotechnology carries a Zacks Rank #3 (Hold).

A better-ranked stock in the same industry is Anthera Pharmaceuticals, Inc. (ANTH - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of todays Zacks #1 Rank stocks here.

Is APOP going up? Or down? Predict to see what others think: Up or Down

Zacks Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public. Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>

Here is the original post:
Cellect Biotechnology (APOP) Jumps: Stock Moves 10.5% Higher - Zacks.com